US 12,109,191 B2
Materials and methods for inhibiting tumor growth
Sadasivan Vidyasagar, Gainesville, FL (US); Reshu Gupta, Gainesville, FL (US); and Stephen Gatto, Norwood, MA (US)
Assigned to AmiLyfe, LLC, Norwood, MA (US); and University of Florida Research Foundation, Incorporated, Gainesville, FL (US)
Appl. No. 16/652,973
Filed by University of Florida Research Foundation, Incorporated, Gainesville, FL (US); and AmiLyfe, LLC, Norwood, MA (US)
PCT Filed Oct. 2, 2018, PCT No. PCT/US2018/054015
§ 371(c)(1), (2) Date Apr. 1, 2020,
PCT Pub. No. WO2019/070750, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/566,787, filed on Oct. 2, 2017.
Prior Publication US 2020/0323820 A1, Oct. 15, 2020
Int. Cl. A61K 31/401 (2006.01); A61K 31/198 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/401 (2013.01) [A61K 31/198 (2013.01); A61P 35/00 (2018.01)] 12 Claims
 
1. A formulation for inhibiting proliferation of cancer cells comprising:
a therapeutically effective amount of free amino acids, the free amino acids consisting essentially of or consisting of free amino acids of:
proline, serine, threonine, tyrosine, and valine; or
proline, serine, threonine, tyrosine, valine, asparagine, and glycine; and
optionally a pharmaceutically acceptable carrier, buffer, electrolyte, adjuvant, or excipient;
wherein a therapeutically effective amount of the formulation inhibits proliferation of cancer cells.